Rathbones Group PLC Cuts Position in Pfizer Inc. $PFE

Rathbones Group PLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 13.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 487,528 shares of the biopharmaceutical company’s stock after selling 72,987 shares during the quarter. Rathbones Group PLC’s holdings in Pfizer were worth $11,818,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in Pfizer by 7.6% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 10,931,822 shares of the biopharmaceutical company’s stock worth $264,987,000 after purchasing an additional 775,358 shares in the last quarter. Parkside Financial Bank & Trust grew its position in shares of Pfizer by 30.4% in the 2nd quarter. Parkside Financial Bank & Trust now owns 60,769 shares of the biopharmaceutical company’s stock worth $1,473,000 after buying an additional 14,170 shares during the last quarter. Aviva PLC grew its position in shares of Pfizer by 7.0% in the 2nd quarter. Aviva PLC now owns 4,239,658 shares of the biopharmaceutical company’s stock worth $102,769,000 after buying an additional 279,010 shares during the last quarter. Prospera Financial Services Inc raised its stake in shares of Pfizer by 108.6% during the 2nd quarter. Prospera Financial Services Inc now owns 179,393 shares of the biopharmaceutical company’s stock worth $4,349,000 after acquiring an additional 93,382 shares in the last quarter. Finally, AE Wealth Management LLC lifted its position in Pfizer by 20.1% during the second quarter. AE Wealth Management LLC now owns 1,172,778 shares of the biopharmaceutical company’s stock valued at $28,428,000 after acquiring an additional 195,961 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 1.6%

Shares of Pfizer stock opened at $24.45 on Monday. The stock has a market cap of $138.99 billion, a PE ratio of 13.00, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54. The firm has a fifty day moving average price of $24.74 and a 200 day moving average price of $24.38. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. Pfizer’s dividend payout ratio is 100.00%.

Wall Street Analyst Weigh In

PFE has been the topic of several analyst reports. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. The Goldman Sachs Group restated a “neutral” rating and set a $26.00 target price on shares of Pfizer in a research note on Wednesday. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $30.00 target price on shares of Pfizer in a research report on Friday, October 31st. Bank of America increased their price target on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Pfizer currently has an average rating of “Hold” and an average target price of $28.18.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.